Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Nectero EAST System** is an investigational, single-use endovascular drug-device combination product developed by Nectero Therapeutics for small- to medium-sized infrarenal abdominal aortic aneurysm. The system uses a dual-balloon catheter to locally deliver a single dose of a stabilizer infusion solution containing pentagalloylglucose into the aneurysmal aortic wall. Pentagalloylglucose binds elastin and collagen, with the intended effect of reinforcing extracellular-matrix structural proteins, stabilizing the aortic wall, and slowing aneurysm enlargement and rupture risk. The product leaves no permanent implant and is being evaluated against surveillance in the randomized Phase 2/3 stAAAble study. ([alcami.com](https://www.alcami.com/news/alcami-supports-phase-ii-iii-trial-supply-of-the-nectero-east-system/))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Nectero EAST System.